NeuroImmune Pharmacology and Therapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 927 - 942
Published: Jan. 1, 2024
Language: Английский
Nature Aging, Journal Year: 2024, Volume and Issue: 4(4), P. 464 - 482
Published: April 15, 2024
Language: Английский
Citations
25
ACS Omega, Journal Year: 2025, Volume and Issue: 10(6), P. 5148 - 5171
Published: Feb. 3, 2025
Alzheimer's disease (AD) is an aging-related irreversible neurodegenerative affecting mostly the elderly population. The main pathological features of AD are extracellular Aβ plaques generated by APP cleavage through amyloidogenic pathway, intracellular neurofibrillary tangles (NFT) resulting from hyperphosphorylated tau proteins, and cholinergic neurodegeneration. However, actual causes unknown, but several studies suggest hereditary mutations in PSEN1 -2, APOE4, APP, TAU genes major perpetrators. In order to understand etiology pathogenesis AD, various hypotheses proposed. These include following hypotheses: amyloid accumulation, tauopathy, inflammation, oxidative stress, mitochondrial dysfunction, glutamate/excitotoxicity, deficiency, gut dysbiosis. Currently approved therapeutic interventions donepezil, galantamine, rivastigmine, which cholinesterase inhibitors (ChEIs), memantine, N-methyl-d-aspartate (NMDA) antagonist. treatment strategies focus on only symptomatic management attenuating symptoms not regeneration neurons or clearance Tau. This review focuses pathophysiology, novel targets, disease-altering treatments such as α-secretase modulators, active immunotherapy, passive natural antioxidant products, nanomaterials, antiamyloid therapy, aggregation inhibitors, transplantation fecal microbiota stem cells, microtubule stabilizers that clinical trials still under investigation.
Language: Английский
Citations
1
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(11), P. 3098 - 3098
Published: May 25, 2024
Alzheimer's disease (AD) causes a significant challenge to global healthcare systems, with limited effective treatments available. This review examines the landscape of novel therapeutic strategies for AD, focusing on shortcomings traditional therapies against amyloid-beta (Aβ) and exploring emerging alternatives. Despite decades research emphasizing role Aβ accumulation in AD pathogenesis, clinical trials targeting have obtained disappointing results, highlighting complexity pathophysiology need investigating other approaches. In this manuscript, we first discuss challenges associated anti-Aβ therapies, including efficacy potential adverse effects, underscoring necessity alternative mechanisms targets. Thereafter, promising non-Aβ-based strategies, such as tau-targeted neuroinflammation modulation, gene stem cell therapy. These approaches offer new avenues treatment by addressing additional pathological hallmarks downstream effects beyond deposition.
Language: Английский
Citations
5
EBioMedicine, Journal Year: 2024, Volume and Issue: unknown, P. 105322 - 105322
Published: Oct. 1, 2024
Language: Английский
Citations
5
Exploration of neuroscience, Journal Year: 2024, Volume and Issue: 3(3), P. 255 - 271
Published: June 27, 2024
Alzheimer’s disease (AD) is a major type of dementia and neurodegenerative disease, characterized by memory loss cognitive decline. Over decades, significant efforts have been dedicated to finding its cause, pathogenic mechanisms, biomarkers for early detection, clinical trials treatment. Earlier approved drugs mainly ameliorated the symptoms AD, until recent years when two targeting amyloid-beta (Aβ) protein were slow down progression disease. This review article encompasses history drug development in treating AD that failed succeeded. Clinicaltrials.org website was systematically searched screened randomized controlled with results posted past 10 years. Among 3,388 trials, 211 interventional studies registered under met eligibility. includes targets discovery such as Aβ, tau, neurotransmitter receptors, neuroinflammation, multi-target studies, repurposing pharmacological agents, non-pharmacological interventions, therapy neuropsychiatric dementia. Current are ongoing no available yet. With vast choices investigated, this aims present some insights into future design contribute our find cure.
Language: Английский
Citations
4
New discovery., Journal Year: 2025, Volume and Issue: unknown, P. 1 - 11
Published: Jan. 10, 2025
Alzheimer's disease (AD) is a neurodegenerative disorder primarily associated with dementia. Emerging evidence highlights the significant role of immune system in AD pathogenesis, positioning immunotherapy as promising area research. This article summarizes adaptive immunity and reviews current treatment strategies. A total 74 out 120 relevant articles were analyzed using keywords such "Alzheimer's disease" "immunity." Findings suggest that may facilitate clearance amyloid-beta (Aβ) tau proteins. Monoclonal antibodies other immunotherapeutic approaches targeting Aβ have progressed from preclinical studies to clinical trials, demonstrating favorable safety tolerability profiles, albeit without achieving substantial efficacy. In conclusion, while plays critical pathogenesis treatment, further investigation into tolerance individual variability essential enhance therapeutic outcomes.
Language: Английский
Citations
0
International Journal of Current Pharmaceutical Research, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10
Published: Jan. 15, 2025
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder primarily affecting individuals over 60. It multifactorial driven by both modifiable factors, such as lifestyle, diet, and prior health conditions, well non-modifiable like age, genetics, family history. The key pathological features of AD include the buildup amyloid β plaques neurofibrillary tangles resulting from hyperphosphorylated tau proteins in brain. Biomarkers protein levels cerebrospinal fluid (CSF) blood are essential for diagnosing tracking progression. Current research focuses on developing drugs targeting multiple aspects pathology, including inflammation, oxidative stress, synaptic dysfunction, accumulation. These treatments aim to slow cognitive decline neuronal damage. Given complexity AD, multi-targeted therapeutic approaches being explored enhance treatment efficacy. This review provides an overview risk biomarkers used diagnosis, latest advances clinical drug development.
Language: Английский
Citations
0
Diagnostics, Journal Year: 2025, Volume and Issue: 15(3), P. 360 - 360
Published: Feb. 4, 2025
Background: Alzheimer’s disease (AD) is a neurodegenerative condition that has no definitive treatment, and its early diagnosis can help to prevent or slow down progress. Structural magnetic resonance imaging (sMRI) the progress of artificial intelligence (AI) have significant attention in AD detection. This study aims differentiate from NC distinguish between LMCI EMCI other two classes. Another goal diagnostic performance (accuracy AUC) sMRI for predicting stages. Methods: In this study, 398 participants were used ADNI OASIS global database including 98 individuals with AD, 102 mild cognitive impairment (EMCI), late (LMCI), 100 normal controls (NC). Results: The proposed model achieved high area under curve (AUC) values an accuracy 99.7%, which very remarkable all four classes: vs. AD: AUC = [0.985], NC: [0.961], [0.951], [0.989], LMCI: [1.000]. Conclusions: results reveal incorporates DenseNet169, transfer learning, class decomposition classify stages, particularly differentiating LMCI. performs well diagnostics at addition, accurate lead prediction prevention slowing before
Language: Английский
Citations
0
Published: Jan. 1, 2025
Language: Английский
Citations
0
Neurological Sciences, Journal Year: 2025, Volume and Issue: unknown
Published: March 20, 2025
Language: Английский
Citations
0